Systematic literature review (SLR) and network meta-analysis (NMA) of first-line therapies (1L) for locally advanced/metastatic urothelial carcinoma (la/mUC).

被引：1
|
作者：
Bloudek, Lisa [1 ]
Hepp, Zsolt [1 ]
Mckay, Caroline [1 ]
Derleth, Christina Louise [1 ]
Lill, Jennifer Susan [1 ]
Lenero, Enrique [1 ]
Wright, Phoebe [1 ]
Ramsey, Scott David [1 ]
Sullivan, Sean D. [1 ]
Devine, Beth [1 ]
机构：
[1] Curta Inc, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
570
引用
收藏
页数：3
相关论文
共 50 条
  • [31] MULTIDIMENSIONAL TREATMENT EFFECT NETWORK META-ANALYSIS TO ESTIMATE SURVIVAL OF THERAPIES FOR PATIENTS WITH FIRST-LINE (1L) ADVANCED OR METASTATIC RENAL CELL CARCINOMA (ARCC) IN FRANCE
    Gittfried, A. M., V
    Lambton, M.
    Nickel, K.
    May, J. R.
    Branchoux, S.
    Kroep, S.
    VALUE IN HEALTH, 2022, 25 (01) : S25 - S25
  • [32] Pembrolizumab plus lenvatinib (P plus L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA).
    Rane, Pratik
    Yan, Kevin
    Schmidinger, Manuela
    Peer, Avivit
    Druyts, Eric
    Burgents, Joseph E.
    Sundaram, Murali
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 421 - 421
  • [33] A NETWORK META-ANALYSIS OF FIRST-LINE SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA
    Singh, B.
    Sharma, A.
    Rai, P.
    Kaur, G.
    Pandey, S.
    VALUE IN HEALTH, 2023, 26 (06) : S26 - S26
  • [34] Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
    Balar, Arjun Vasant
    Galsky, Matt D.
    Loriot, Yohann
    Dawson, Nancy Ann
    Necchi, Andrea
    Srinivas, Sandy
    Joseph, Richard Wayne
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Drakaki, Alexandra
    Duran, Ignacio
    Rosenberg, Jonathan E.
    Powles, Thomas
    Hoffman-Censits, Jean H.
    Cui, Na
    Mariathasan, Sanjeev
    Thastrom, Ann Christine
    Abidoye, Oyewale O.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [35] First-line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis
    Fong, Khi Yung
    Zhao, Joseph Jonathan
    Sultana, Rehena
    Lee, Joycelyn Jie Xin
    Lee, Suat Ying
    Chan, Stephen Lam
    Yau, Thomas
    Tai, David Wai Meng
    Sundar, Raghav
    Too, Chow Wei
    LIVER CANCER, 2023, 12 (01) : 7 - 18
  • [36] First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis
    Rousseau, Benoit
    Kempf, Emmanuelle
    Desamericq, Gaelle
    Boissier, Emilie
    Chaubet-Houdu, Marie
    Joly, Charlotte
    Saldana, Carolina
    Boussion, Helene
    Neuzillet, Cindy
    Macquin-Mavier, Isabelle
    Oudard, Stephane
    Salomon, Laurent
    de la Taille, Alexandre
    Tournigand, Christophe
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 107 : 44 - 53
  • [37] First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
    Hahn, Andrew W.
    Klaassen, Zachary
    Agarwal, Neeraj
    Haaland, Benjamin
    Esther, John
    Ye, Xiang Y.
    Wang, Xuechen
    Pal, Sumanta K.
    Wallis, Christopher J. D.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 708 - 715
  • [38] ECONOMIC IMPACT OF FIRST-LINE (1L) IMMUNOTHERAPIES IN ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Sarri, G.
    Freitag, A.
    Kazmierska, P.
    Lin, B.
    Pawar, V
    Zhang, X.
    VALUE IN HEALTH, 2020, 23 : S443 - S444
  • [39] Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
    Mastrantoni, L.
    Beccia, V.
    Chiaravalli, M.
    Di Bello, A.
    Spring, A.
    Barone, D.
    Schietroma, F.
    Maratta, M. G.
    Trovato, G.
    Bagala, C.
    Bensi, M.
    Alfieri, S.
    Quero, G.
    Tortora, G.
    Salvatore, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S920 - S920
  • [40] First-line (1L) Lorlatinib in Patients with ALK-Positive aNSCLC: Updated Network Meta-Analysis (NMA) and Review of Ten NMAs
    Ou, S. -H. I.
    Kilvert, H.
    Candlish, J.
    Jaiyeola, C.
    Polli, A.
    Thomaidou, D.
    Le, H.
    Lee, B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S358 - S358
12345